Valneva SE

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

09 Jan 2026 01:00:00 By Nasdaq GlobeNewswire

Valneva SE - Declaration of voting rights - December 2025

08 Jan 2026 12:30:00 By Nasdaq GlobeNewswire

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

31 Dec 2025 11:45:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

10 Dec 2025 11:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: November 30, 2025

05 Dec 2025 12:34:15 By Nasdaq GlobeNewswire

Valneva to Further Consolidate its Operations in France 

26 Nov 2025 11:30:00 By Nasdaq GlobeNewswire

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

26 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

20 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2025

05 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

04 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

27 Oct 2025 12:45:00 By Nasdaq GlobeNewswire

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

06 Oct 2025 11:35:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: September 30, 2025

06 Oct 2025 01:30:00 By Nasdaq GlobeNewswire

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

30 Sep 2025 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2025

03 Sep 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

03 Sep 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

25 Aug 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

18 Aug 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

12 Aug 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

07 Aug 2025 01:17:50 By Nasdaq GlobeNewswire